A review of contemporary prevention strategies for radiocontrast nephropathy: A focus on fenoldopam and N-acetylcysteine

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Lepor, Norman E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fenoldopam; Intravenous hydration; N acetylcysteine; Radiocontrast nephropathy

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ANTIHYPERTENSIVE AGENT; CONTRAST MEDIUM; CREATININE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; FENOLDOPAM; FUROSEMIDE; MANNITOL; SCAVENGER; SODIUM CHLORIDE;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE MODEL; DIURESIS; DOG; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYDRATION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY ISCHEMIA; KIDNEY TUBULE; NONHUMAN; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE;

ACETYLCYSTEINE; ANIMALS; CONTRAST MEDIA; DIABETES COMPLICATIONS; DOGS; DOPAMINE AGONISTS; EVALUATION STUDIES; FENOLDOPAM; FLUID THERAPY; FREE RADICAL SCAVENGERS; HUMANS; ISCHEMIA; KIDNEY DISEASES; KIDNEY TUBULES; MODELS, ANIMAL;

EID: 0037242172     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Deray G, Jacobs C. Radiocontrast nephrotoxicity: a review. Invest Radiol. 1995;30:221-225.
2. Brezis M, Rosen S, Silva P, Epstein FH. Renal ischemia: a new perspective. Kidney Int. 1984;26:375-383.
3. Nygren A, Ulfendahl HR, Hansell P, Erikson U. Effects of intravenous contrast media on cortical and medullary blood flow in the rat kidney. Invest Radiol. 1988;23:753-761.
4. Mathur V. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med. 2001;2(suppl 1): S4-S8.
5. Bakris GL, Gaber AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990;175:57-60.
6. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994,331:1416-1420.
7. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83;260-263, A5.
8. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study: Prevention of Radiocontrast induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999;33:403-411.
9. Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int. 1992;41:1274-1279.
10. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy. Arch Intern Med. 2002;162:329-336.
11. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fendoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970-977.
12. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161-168.
13. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int. 1999;56:206-210.
14. Madyoon H. Clinical experience in the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med. 2001;2(suppl 1):S26-S30.
15. Kina AA, Sharma S. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med. 2001;2(suppl 1):Sl9-S25.
16. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894-903.
17. Stone G, Tumlin J, Madyoon H, Lepor N, McCullough P, Mathur V, Murray P, O'Neil W. Design and rational of CONTRAST-A Prospective randomized trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. Rev Cardiovasc Med. 2001;2(suppl 1): S31-S36.
18. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
19. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine contrast agent-associated nephropathy. J Am Coll Cardiol. 2002;40:298-303.
20. Diaz-Sandoval LJ, Kosowsky BD; Losordo DW. Acetylcysteine to prevent anglography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356-358.
21. Caputo C, Dokko J, Durham J, et al. A randomized controlled trial of n-acetyl cysteine to prevent contrast nephropathy following coronary angiography. Presented at: National Kidney Foundation Clinical Nephrology Meetings 2002; April 17-21, 2002; Chicago, IL.